Oncology News | pharmaphorum

News

NICE’s track record in cancer drugs: the impact of the CDF and the role of interim funding

Exelixis takes $20m option Iconic/Zymeworks' cancer ADC

Exelixis has taken a $20 million option to license in an antibody-drug conjugate cancer (ADC) drug from Iconic, with clinical trials expected to start next year.

News

Janssen J&J Johnson and Johnson pharmaceutical companies

J&J files lung cancer bispecific amivantamab for FDA approva...

Johnson & Johnson has filed its bispecific antibody amivantamab to the FDA, hoping to muscle into the big market for drugs that are used to treat EGFR-positive non-small cell lung cance

News

DNA strand and Cancer Cell Oncology Research Concept 3D rendering

Merck KGaA signs DNA damage response cancer deal with Artios...

Germany’s Merck KGaA has joined with UK-based Artios Pharma in a potential multi-billion dollar deal to investigate novel DNA damage response targets in cancer.

News

Roche, Blueprint raise pressure on Lilly with new Gavreto ap...

The FDA has cleared Roche and Blueprint Medicine’s Gavreto for a new use in RET-mutated thyroid cancer, putting it on a level playing field with Eli Lilly’s rival therapy Retevmo.<

News

Chronic lymphocytic leukemia (CLL) is a type of cancer of the blood and bone marrow - the spongy tissue inside bones where blood cells are made.

TG Therapeutics challenges Roche with FDA filing for CLL dru...

US biotech TG Therapeutics has begun a rolling filing with the FDA for its combination therapy for chronic lymphocytic leukaemia, in a challenge to Roche.

News